In recent years, breast cancer has become one of the fastest rising malignant tumors in China, and the incidence rate is increasing dramatically at an annual rate of 3% to 4%. In the media conference “The Importance of High Quality HER2 Testing for Individualized Treatment of Breast Cancer” held on October 26, experts at the conference unanimously called for all breast cancer patients to establish awareness of HER2 testing and actively cooperate with doctors for proper diagnosis to prevent HER2 patients from being missed or misdiagnosed. HER2, also known as human epidermal growth factor receptor-2, is an important prognostic factor for breast cancer. Sun Qiang, director of breast surgery at Peking Union Medical College Hospital, said that among all breast cancer patients, two to three out of 10 are HER2-positive, and compared with other breast cancer patients, HER2-positive breast cancer patients have more malignant tumors, progress faster, are more likely to recur and metastasize, and have significantly shorter disease-free survival, making them the “most dangerous breast cancer”. It is the “most aggressive breast cancer”. ”The survival time of HER2-positive breast cancer patients is only half of that of HER2-negative patients if they just receive conventional comprehensive treatment. If HER2 status is determined early and targeted treatment is used, the survival chance of HER2-positive patients may approach that of HER2-negative patients.” Sun Qiang said. According to Chen Jie, vice president of Peking Union Medical College Hospital, the most common method used clinically for HER2 detection is fluorescence in situ hybridization (FISH), but FISH technology cannot preserve results for a long time, is difficult to operate, takes a long time and must be observed by a pathologist under a dark field of view for tissue cell morphology, which leads to great difficulty in quality assurance and promotion. Chen Jie believes that the solution to this problem is to achieve full automation of pathology testing, minimizing manual operations and thus providing patients with more accurate and faster HER2 testing. According to the report, the SISH technology used by the Roche Diagnostics BenchMark series of fully automated immunohistochemistry testing platform can be read with a conventional microscope without manual operation and with higher sensitivity. ”The fully automated immunohistochemistry test and molecular detection platform reduces the manual operation time by 80%, which can greatly shorten the cycle time of the test, and more importantly, the platform substantially improves the consistency and accuracy of the test results, allowing patients to receive timely and effective treatment and reducing treatment delays and waste of resources due to inappropriate treatment.”